Finally, experience of trying to develop novel therapeutic brokers for these patients (see previous sections) leads to the conclusion that targeting one or even a
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
Finally, experience of trying to develop novel therapeutic brokers for these patients (see previous sections) leads to the conclusion that targeting one or even a